Des(1-3) IGF-1 · short analog
IGF-1 DES
Cited range High-signal
What it is
IGF-1 DES is IGF-1 with the first three amino acids removed. That change makes it less sticky to binding proteins, so a larger share can act near the injection site for a short window.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- People use the local-injection story: more of the signal stays in the muscle you just trained.
- It is a growth-factor, not a secretagogue — it is closer to the “do the work” end of the GH/IGF chain.
- Hypoglycemia and tissue-growth caution still apply. This is not a beginner recovery peptide.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Reduced IGFBP binding increases free analog at the tissue. IGF-1 receptor activation drives protein synthesis, glucose uptake, and cell survival pathways.
Possible side effects / caveats
Low blood sugar, local irritation, and the usual unknown-long-term growth-factor questions. Quality of research vials varies wildly.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 20–50 mcg | Often pre/post local session in community notes | Not a labeled dose |
| Cited range | Up to ~100 mcg/day | Split local sites | Upper chatter; more risk of systemic IGF effects |